In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mass. Prop 65 copy cat bill likely would trigger "almost no warnings" -- EDF attorney Roe.

This article was originally published in The Tan Sheet

Executive Summary

MASS. PROP 65 BILL WOULD TRIGGER "ALMOST NO WARNINGS," EDF ATTORNEY Roe asserted at a May 5 hearing before the state Senate/House Natural Resources Committee. Under the "Right to Know" bill (S 488), introduced by committee Chair Sen. Lois Pines (D), the Massachusetts Department of Public Health would draft and update a yearly list of toxic substances that would trigger warnings on consumer product labels. An identical bill has been introduced in the House by Rep. Douglas Peterson (D). The proposed legislation closely mirrors California's Proposition 65, which was voted into law by a 1986 ballot referendum. Environmental Defense Fund Senior Attorney David Roe is a co-author of California's Prop 65. Similar legislation has died in Massachusetts several times in the last few years.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel